NL-OMON24708招募中不适用
Bortezomib maintenance therapy in newly diagnosed patients with mantle cell lymphoma, responsive on rituximab combined with CHOP and high dose Ara-C and after BEAM with auto PSCT rescue.
Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 7041560Fax: 010 7041028e-mail: hdc@erasmusmc.nl0 个研究点目标入组 90 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 90
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients with histologically and immunologically proven diagnosis of MCL (WHO classification);
- •2. Ann Arbor stage II ¨C IV;
排除标准
- •1. Renal failure (creatinine clearance < 50 ml/min);
- •2. Known hypersensitivity to murine antibodies, boron or mannitol;
研究者
相似试验
进行中（未招募）
不适用
Bortezomib as consolidation therapy in patients aged 60 years and younger with multiple myelomamultiple myeloma in patients aged 60 years and younger having been treated before initiation of the study with a high dosage chemotherapy with melphalane followed by an autologous or allogenic stemcell transplantationMedDRA version: 14.1Level: PTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-004948-31-DEJANSSEN-CILAG GmbH
进行中（未招募）
不适用
Bortezomib as consolidation therapy in patients aged 61-75 years with multiple myelomamultiple myeloma in patients aged 61-75 years having been treated before initiation of the study with a high dosage chemotherapy with melphalane followed by an autologous stemcell transplantationMedDRA version: 15.0Level: PTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-004947-73-DEJANSSEN-CILAG GmbH190
已完成
不适用
Maitenance therapy with bortezomib for multiple myeloma after autologus stem cell transplantatiomultiple myelomaJPRN-UMIN000007188niversity Of Tokyo Hospital, Department of Hematology and Oncology20
已完成
不适用
Phase II study of bortezomib maintenance therapy for multiple myeloma patientsMultiple MyelomaJPRN-UMIN000013912ational Hospital Organization Disaster Medical Center of Japan96
已完成
2 期
An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib TherapyMultiple MyelomaNCT00216697Janssen Pharmaceutical K.K.13